150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?
Published: Jun 1, 2021
Abstract
Introduction
Sodium-glucose co-transporter (SGLT2) inhibition has been shown to reduce the risk of cardiovascular death or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF) with or without type 2 diabetes mellitus (T2DM). Since publication of the DAPA-HF1 and EMPEROR-HF2 trials and UK NICE approval,3 SGLT2 inhibitor prescription has been increasing for patients with...Paper Details
Title
150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?
Published Date
Jun 1, 2021
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History